Abnormal shifts in global climate, leading to extreme weather, significantly threaten the safety of individuals involved in outdoor activities. Hypothermia-induced coma or death frequently occurs in clinical and forensic settings. Despite this, the precise mechanism of central nervous system injury due to hypothermia remains unclear, hindering the development of targeted clinical treatments and specific forensic diagnostic indicators. The GEO database was searched to identify datasets related to hypothermia. Post-bioinformatics analyses, DEGs, and ferroptosis-related DEGs (FerrDEGs) were intersected. GSEA was then conducted to elucidate the functions of the Ferr-related genes. Animal experiments conducted in this study demonstrated that hypothermia, compared to the control treatment, can induce significant alterations in iron death-related genes such as PPARG, SCD, ADIPOQ, SAT1, EGR1, and HMOX1 in cerebral cortex nerve cells. These changes lead to iron ion accumulation, lipid peroxidation, and marked expression of iron death-related proteins. The application of the iron death inhibitor Ferrostatin-1 (Fer-1) effectively modulates the expression of these genes, reduces lipid peroxidation, and improves the expression of iron death-related proteins. Severe hypothermia disrupts the metabolism of cerebral cortex nerve cells, causing significant alterations in ferroptosis-related genes. These genetic changes promote ferroptosis through multiple pathways.
Survivors of severe hypothermia frequently exhibit cognitive impairments. However, the underlying mechanisms remain inadequately understood. In order to reveal the scientific problem of cognitive dysfunction caused by severe hypothermia, providing an experimental basis for clinical treatment, this study utilized animal models and combined cognitive behavioral, morphological, and molecular biological experiments. The results showed that severe hypothermia leads to an accumulation of iron ions in the cerebral cortex tissue exceeding 70%, while increased Acyl-coenzyme A synthetase long-chain family member 4 (ACSL4) expression enhances sensitivity to ferroptosis. This process results in a nearly 50% decrease in glutathione (GSH) expression and over 50% degradation of glutathione peroxidase 4 (GPX4), leading to GPX4 deactivation and increased lipid peroxidation, which in turn nearly doubles the levels of oxidative products such as MDA and 4NHE. Notably, ferroptosis inhibition using Ferrostatin-1 (Fer-1) effectively mitigates the degenerative death of cerebral cortical neurons induced by severe hypothermia, significantly improving the associated cognitive deficits. These findings suggest that severe hypothermia may induce ferroptosis in cortical neurons through the Nrf2/SLC7A11/GSH/GPX4 signaling axis. Targeted inhibition of ferroptosis has the potential to be a promising therapeutic direction for the prevention and treatment of cognitive impairment caused by severe hypothermia.
Central sleep apnea (CSA), characterized by unstable ventilatory control during sleep, poses significant health risks, particularly in patients with cardiovascular comorbidities. This bibliometric analysis evaluated 1,687 CSA-related publications (2004–2025) from the Web of Science Core Collection. Annual publications surged post-2016, peaking in 2021 (115 articles), reflecting growing research interest. The U.S. and Germany dominated contributions, with American Journal of Respiratory and Critical Care Medicine as the top journal. Keyword analysis revealed three focal areas: CSA-heart failure interactions (e.g., mortality, ejection fraction), CSA mechanisms (e.g., hypercapnia, chemosensitivity), and clinical management (e.g., adaptive servo-ventilation, phrenic nerve stimulation). Emerging trends include pediatric CSA, pathophysiology, and AI-driven diagnostics. International collaboration and multidisciplinary approaches are critical for advancing CSA research. Limitations include database constraints and evolving literature. This study maps CSA research trends, highlights gaps, and guides future investigations into mechanisms, biomarkers, and personalized therapies.
Background: Hypothermia has been strongly associated with human diseases; it affects life safety. Therapeutic hypothermia generates good results for certain diseases, without serious complications. In clinical practice, research on the treatment of hypothermia and severe hypothermia-induced diseases have achieved fruitful results. However, no bibliometric analysis has been conducted. In this study, we explored the research status and hotspots of hypothermia and human diseases by conducting a bibliometric analysis.Methods: Articles on hypothermia and human diseases were collected from the Web of Science Core Collection. From 1 January 2005 to 31 August 2024, A total of 1,553 articles were retrieved. After excluding irrelevant articles, 706 articles were analyzed.Results: The United States and China published the maximum number of research articles on hypothermia and human diseases. Among institutes, Johns Hopkins University and Harvard University published the maximum number of research articles. Scholars, including Ishikawa Takaki, Maeda Hitoshi, and Michiue Tomomi, constituted a highly productive group of authors. The journal, Therapeutic Hypothermia and Temperature Management published the highest number of articles, and Nature Reviews Drug Discovery had the highest impact factor. Cluster analysis of all keywords primarily focused on the following research directions: (i) hypothermia-related injury, (ii) hypothermia treatment, and (iii) the mechanism underlying hypothermia.Conclusion: This bibliometric study comprehensively summarizes the impact of hypothermia on human diseases and the research overview of the use of moderate hypothermia for treatment. This paper clarifies the research status, frontiers and hotspots, and also puts forward new insights for hypothermia research: strengthen research cooperation to improve the depth of research, increase support for areas with insufficient medical conditions; in the future, single-cell multiomics technology will be used to explore cell types sensitive to different low temperatures and corresponding molecular mechanisms; non-coding RNA regulation will be used to achieve precision treatment of hypothermia diseases; Organoids will be an important object of hypothermia research. These research insights can provide reference for researchers.
Background and objective: Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and tau pathology, with mTORC1 hyperactivation implicated in disease pathogenesis via suppression of autophagy. However, systematic evidence regarding its key upstream repressor, TSC1, in human AD brains remains limited. Methods: Using an integrated, multi-level bioinformatic approach combining RNA-seq, neuropathological, and clinical data from the ROSMAP cohort, we comprehensively investigated the TSC1-mTORC1 axis in AD. Gene co-expression network analysis and gene set enrichment analysis were applied to contextualize TSC1 within disease-associated molecular networks. Results: Our analysis revealed significant TSC1 downregulation and concomitant mTOR and RPTOR upregulation in AD brains. Critically, lower TSC1 expression was strongly correlated with higher Aβ plaque density, greater tau tangle burden, worse global cognitive performance, and an exacerbated neuroinflammatory microenvironment characterized by increased microglial and astrocytic activation. Gene co-expression network analysis positioned TSC1 within a disease-associated module showing the strongest association with AD pathology. Gene set enrichment analyses further demonstrated that the TSC1 low-expression phenotype was associated not only with suppression of autophagy-related pathways but also with significant enrichment of broad pro-inflammatory and immune response pathways. Conclusion and discussion: These integrated human data provide compelling evidence that TSC1 deficiency is a hallmark of AD and is associated with mTORC1 hyperactivation, aggravated amyloid-tau pathologies, cognitive impairment, and neuroinflammation. These findings are consistent with a model in which TSC1 deficiency and mTORC1 hyperactivation may contribute to AD pathophysiology, thereby nominating the TSC1-mTORC1 axis and its associated inflammatory networks as promising multi-faceted therapeutic targets. Future replication in independent cohorts is warranted to assess the generalizability of these findings.